NMTCGeneral
NeuroOne Medical Technologies Announces Restatement of Financial Results for Quarter Ending
NeuroOne Medical Technologies Corporation has announced a restatement of its financial results for the quarter ending March 31, 2026, due to a revenue overstatement caused by customer order modifications. The company confirmed that this restatement will not impact its product revenue guidance for fiscal year 2026, which remains at least $10.5 million. Despite the need for correction, NeuroOne's ongoing business operations and growth strategies are reported to be stable. The company intends to amend its financial statements and improve internal controls over financial reporting.
Read more →NMTCGeneral
NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update Product Revenue of $2.4 Million up 72% Year Over Year Successfully Completed 16 Trigeminal Neuralgia Cases to Date, With All Patien
NeuroOne Medical Technologies Corporation has reported financial results for Q2 2026, showing a remarkable 72% increase in product revenue amounting to $2.4 million. The company successfully completed 16 trigeminal neuralgia procedures, with all patients reportedly pain-free. While operational expenses remained consistent, the quarterly net loss decreased slightly when compared year-on-year. The report also highlights future growth prospects with the continued expansion of its product lines and international market reach.
Read more →NMTCGeneral
NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026 Nearly 50% of all Ablations Since OneRF Ablation System Product Launch in 2024 were Performed in Fi
NeuroOne Medical Technologies Corporation reported its financial results for the first quarter of fiscal 2026, highlighting product revenue expectations of at least $10.5 million. During this quarter, nearly half of all ablations using the OneRF Ablation System since its launch were completed. The company successfully concluded nine cases for trigeminal neuralgia, with all patients reporting pain relief. However, product revenues faced a slight decline from the previous year, and the company recorded a net loss during this period.
Read more →NMTCGeneral
NeuroOne Appoints Jason Mills to the Board of Directors Veteran Med-Tech Research Analyst & Public Company Executive to Bring Strategic Experience, Industry Relationships and Vision to the Board
NeuroOne Medical Technologies Corporation has appointed Jason Mills to its Board of Directors, effective December 18, 2025. Mills brings over two decades of experience in med-tech investment analysis and currently serves as Executive Vice President of Strategy at Penumbra, Inc. His extensive background, including awards for his equity research, is expected to provide valuable insights as NeuroOne progresses with its clinical and corporate goals. The appointment is seen as a strategic move to enhance the company's value in transforming the diagnosis and treatment of neurological disorders.
Read more →NMTCGeneral
NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results with Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross Margin & Total Revenue Growth of 163% to $9.1 Million for Fiscal Year 2025 Revenue
NeuroOne Medical Technologies Corporation announced its fiscal 2025 financial results, showcasing robust growth. The company achieved a remarkable 907% increase in product revenue in the fourth quarter, reaching $2.7 million, and a total revenue increase of 163% for the fiscal year, totaling $9.1 million. Contributing to this success was the strong performance of the OneRF Ablation System, alongside achieving FDA 510(k) clearance for the OneRF Trigeminal Nerve Ablation System. The balance sheet also strengthened, positioning the company for further expansion and development in 2026.
Read more →NMTCConferences/Events
NeuroOne Announces Preliminary Unaudited Product Revenue Growth of 163% to Record $9.1 Million, Invitation to Join Virtual Investor Webinar Tomorrow at 8:30am
NeuroOne Medical Technologies Corporation has reported a significant preliminary unaudited product revenue growth of 163%, reaching a record $9.1 million for the fiscal year ending September 30, 2025. This growth is attributed to increased customer interest and favorable outcomes associated with its OneRF Ablation system for epilepsy patients. The company will provide further financial details in December 2025 and is hosting a virtual investor webinar on October 7, 2025, to discuss recent developments.
Read more →NMTCConferences/Events
NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
NeuroOne Medical Technologies Corporation will participate in the Sidoti Small-Cap Conference on September 17-18, 2025. CEO Dave Rosa and CFO Ron McClurg will present on September 17 and hold one-on-one meetings with investors. The company reported a 105% revenue increase and received FDA clearance for its Trigeminal Nerve Ablation System.
Read more →NMTCFDA Updates
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne Medical Technologies has received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, designed to treat trigeminal neuralgia, a chronic facial pain condition. This minimally invasive system utilizes radiofrequency energy to create lesions in the trigeminal nerve, potentially improving patient outcomes. A limited commercial launch is targeted for late 2025.
Read more →NMTCGeneral
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
NeuroOne Medical Technologies Corporation reported a significant 105% increase in revenue for the third quarter of fiscal year 2025, alongside an expansion of gross profit margin to 53.9%. The company is progressing with its OneRF® Ablation system and has submitted a 510(k) application to the FDA for a new product. Despite a net loss of $1.5 million, the company remains optimistic about future growth and profitability.
Read more →NMTCConferences/Events
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update
NeuroOne Medical Technologies Corporation will release its financial results for the third quarter of fiscal year 2025 on August 14, 2025. The company will also host an investor conference call to discuss these results and provide a corporate update. Interested participants can join the call via provided dial-in information.
Read more →NMTCGeneral
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
NeuroOne Medical Technologies Corporation has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office. This patent, titled 'Methods for Making Probe Devices and Related Devices,' covers innovative methods for creating neural probe devices. The company expects the patent to be issued soon, enhancing its intellectual property portfolio, which includes 17 patents related to electrode technologies.
Read more →NMTCGeneral
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
NeuroOne Medical Technologies Corporation announced that Clara, an early patient treated with the OneRF® Ablation System, has surpassed one year of being seizure-free. This milestone highlights the effectiveness of the device, which is FDA-cleared for both diagnostic and therapeutic use. The company aims to leverage this technology for further applications, including treating facial pain.
Read more →NMTCGeneral
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
NeuroOne Medical Technologies Corporation has appointed Emily Johns as General Counsel and Corporate Secretary. This strategic hire is expected to strengthen the management team and reduce legal costs. Johns brings extensive experience in corporate governance and has previously worked with NeuroOne on transactional matters. She expressed excitement about joining the company during a pivotal time.
Read more →NMTCConferences/Events
NeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025
NeuroOne Medical Technologies Corporation will participate in the MedInvest MedTech, AI & Digital Health Conference on June 3-4, 2025, in San Francisco. CEO Dave Rosa will meet with investors during the event, which will include discussions on medical devices and digital health technologies. This participation highlights NeuroOne's commitment to advancing surgical care for neurological disorders.
Read more →NMTCFDA Updates
NeuroOne Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6% Filed 510(k)Submission with FDA for OneRF Trigeminal Nerve Ablation System to Treat Facial Pain Ahead o
NeuroOne Medical Technologies Corporation (NMTC) has reported its financial results for the second quarter of fiscal year 2025, showcasing substantial improvements in gross margins and product revenues. The company achieved a gross margin of 55.6%, significantly up from the previous year's 28.3%. Additionally, NeuroOne filed a 510(k) submission to the FDA for its OneRF Trigeminal Nerve Ablation System ahead of schedule and successfully raised $8.2 million to fund its operations and strategic growth initiatives through at least fiscal 2026. The company anticipates a considerable increase in product revenue for the fiscal year 2025, compared to the past year.
Read more →NMTCGeneral
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
NeuroOne Medical Technologies Corporation has appointed Dr. Parag Patil as Chief Medical Advisor, enhancing its clinical development strategy. Dr. Patil, a seasoned neurosurgeon and engineer, has served on the company's Scientific Advisory Board since 2018 and will leverage his expertise to advance NeuroOne's technology for treating neurological disorders. The company focuses on developing minimally invasive solutions to improve patient outcomes. However, the company faces challenges related to capital requirements and compliance with Nasdaq regulations.
Read more →NMTCConferences/Events
NeuroOne to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
NeuroOne Medical Technologies Corporation will report its financial results for the second quarter of fiscal year 2025 on May 13, 2025. The conference call is scheduled for 8:30 a.m. Eastern Time and will include a corporate update and Q&A session. The company specializes in minimally invasive solutions for various neurological disorders and aims to improve patient outcomes.
Read more →NMTCFDA Updates
NeuroOne Completes FDA Submission for the OneRF Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne Medical Technologies Corporation has completed its FDA 510(k) submission for the OneRF Trigeminal Nerve Ablation System, intended to treat trigeminal neuralgia. The submission was made ahead of schedule and uses advanced radiofrequency technology to offer a minimally invasive alternative to traditional treatments. If cleared by the FDA, the company anticipates generating revenue from this system by late calendar year 2025, building on its success in neurosurgical applications. The technology has already demonstrated a high rate of initial pain relief and aims to enhance patient safety and comfort.
Read more →NMTCGeneral
NeuroOne Issues Letter to Shareholders
NeuroOne Medical Technologies Corporation has issued a letter to shareholders, highlighting its achievements and financial outlook. The company has secured $8.3 million in funding and expanded its partnership with Zimmer Biomet, granting exclusive distribution rights for a key product. Additionally, NeuroOne has confirmed that its domestic supply chain should not be affected by global tariffs. They anticipate significant revenue growth in fiscal year 2025, projecting product revenues between $8.0-$10.0 million.
Read more →NMTCGeneral
NeuroOne OneRF Technology Success Story Featured on Fox News
NeuroOne Medical Technologies Corporation recently gained national attention when Fox News featured the successful treatment of a pediatric patient using its OneRF® Ablation System. The 17-year-old patient, Clara Fuller, experienced a dramatic reduction in seizures, going from up to ten nightly seizures to being completely seizure-free following the procedure. This marks a significant milestone as Clara is the first pediatric patient to undergo treatment with this innovative technology focused on improving surgical care for neurological disorders. The company's technology highlights its commitment to advancing minimally invasive solutions for patients with epilepsy and other neurological conditions.
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock
NeuroOne Medical Technologies Corporation has announced the pricing of a public offering of 16 million shares of its common stock at $0.50 per share, aiming to raise $8 million. The offering is being managed by Ladenburg Thalmann & Co. Inc. and is expected to close on or about April 7, 2025. The net proceeds will be allocated for general working capital purposes, supporting the company’s operations in improving surgical care options for neurological disorders.
Read more →NMTCGeneral
NeuroOne CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace - Update
NeuroOne CEO Dave Rosa discussed new advancements in epilepsy treatment featuring the company's OneRF® Ablation System on Today’s Marketplace. The device is the first FDA-cleared solution that integrates brain activity recording and RF ablation. This approach aims to improve outcomes for patients who have not responded to traditional medication and may reduce the need for multiple surgeries. The discussion highlighted the potential of the technology and its significance in addressing the unmet needs of epilepsy patients globally.
Read more →NMTCConferences/Events
NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy
NeuroOne Medical Technologies Corporation's CEO, Dave Rosa, participated in an interview with Today's Marketplace to discuss advancements in epilepsy treatments. The focus was on the company's OneRF™ ablation system, which is the first device to both record brain activity and perform RF ablation. This innovative system targets patients unresponsive to conventional medication, aiming for a more effective and streamlined procedure. The conversation highlighted a successful case where a teenage patient experienced significant improvement in seizure management after using the system.
Read more →NMTCFDA Updates
NeuroOne Accelerates Timeline of 510(k) Submission to FDA for the OneRF Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne Medical Technologies Corporation has announced an accelerated timeline for its 510(k) submission to the FDA for the OneRF Trigeminal Nerve Ablation System, now expected in May 2025. This system is aimed at treating facial pain caused by trigeminal neuralgia, a condition that has a growing market expected to surpass $416 million by 2030. If cleared by the FDA, the company anticipates the potential to generate revenue from this treatment in late 2025, earlier than previously forecasted. The company's CEO mentioned the importance of these advancements within their existing technology portfolio and informed stakeholders about future developments.
Read more →NMTCConferences/Events
NeuroOne to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference on March 19, 2025. CEO Dave Rosa will host a virtual presentation and engage in one-on-one meetings during the event. The company focuses on developing minimally invasive solutions for various neurological disorders, including epilepsy and Parkinson's disease, with an emphasis on improving patient care and reducing costs.
Read more →NMTCGeneral
NeuroOne Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in
NeuroOne Medical Technologies Corporation reported its financial results for the first quarter of fiscal 2025, showing a total revenue of $6.3 million. This figure includes $3.3 million from product revenue and a $3.0 million one-time upfront payment from Zimmer Biomet. The company's gross profit from product sales was 58.9%, with net income of $1.8 million for the period. NeuroOne anticipates continued revenue growth in fiscal 2025 and plans to submit a new 510(k) application to the FDA for a trigeminal nerve ablation system in the coming months.
Read more →NMTCConferences/Events
NeuroOne to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is set to announce its financial results for the first quarter of fiscal year 2025 on February 12, 2025. The company specializes in developing minimally invasive solutions for various neurological disorders. In addition to the financial results, management will host a conference call to provide a corporate update and address questions from investors. This event aims to enhance transparency and communication with stakeholders.
Read more →NMTCGeneral
NeuroOne Regains Compliance with Nasdaq Listing Requirements
NeuroOne Medical Technologies Corporation has announced that it has regained compliance with Nasdaq listing requirements for minimum share price standards. This follows a letter received from Nasdaq indicating that the company's bid price deficiency has been cured. The Nasdaq hearing previously scheduled has now been canceled. The company also reported a record revenue of $6.2 million for the first quarter of fiscal 2025, signaling strong performance in their market segment.
Read more →NMTCGeneral
NeuroOne Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue
NeuroOne Medical Technologies Corporation (NMTC) has announced a preliminary unaudited revenue of $6.2 million for the first quarter of fiscal 2025, marking a significant increase from $1.0 million in the same period last year. This revenue includes a one-time collaboration payment of $3.0 million from Zimmer Biomet, which is part of an expanded distribution agreement. The company has reported a product revenue rise of 227% to $3.2 million. This performance positions NeuroOne to maintain a positive outlook for the fiscal year ahead.
Read more →NMTCConferences/Events
NeuroOne Announces Change of Virtual Investor Webinar to Friday, January 10, 2024
NeuroOne Medical Technologies Corporation announced a rescheduling of its Virtual Investor Webinar to January 10, 2025, due to a closure of U.S. equity markets. The CEO, Dave Rosa, will outline the company's business model and highlight recent achievements, including a new distribution agreement with Zimmer Biomet. Following a reported revenue increase of 77% for fiscal year 2024, the company is projecting product revenue growth of 132% to 190% for fiscal year 2025. The webinar will also include a Q&A session accessible through a provided link.
Read more →NMTCConferences/Events
NeuroOne Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced a virtual investor webinar scheduled for January 9, 2025, to discuss its business model and revenue expectations. The CEO, Dave Rosa, will provide insights into the company's operations and recent milestones such as a substantial 77% revenue growth in fiscal year 2024. Additionally, the company anticipates a significant increase in product revenue for fiscal year 2025, aiming for between $8 and $10 million. This growth is attributed to their expanded distribution agreement with Zimmer Biomet, a leading medical device manufacturer.
Read more →NMTCGeneral
NeuroOne Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025 Company's Exclusive Distribution Agreement with Zimmer Biomet
NeuroOne Medical Technologies Corporation reported a 77% increase in product revenue, reaching $3.5 million for fiscal 2024. The company anticipates further growth, projecting product revenue to reach at least $8 million in fiscal 2025 due to an exclusive distribution agreement with Zimmer Biomet. Despite this, the company's net loss increased to $12.3 million in fiscal 2024. The report also highlighted a reduction in fourth quarter revenue due to a purchase order cancellation related to product line transitions.
Read more →NMTCConferences/Events
NeuroOne to Report Fourth Quarter and Fiscal Year 2024 Financial Results on December 17 at 9:00 a.m. Eastern Time
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will report its financial results for the fiscal fourth quarter and year ended September 30, 2024, on December 17, 2024. The company will host an investor conference call at 9:00 a.m. Eastern Time to discuss the results, provide a corporate update, and engage in a Q&A session. NeuroOne aims to improve surgical care for patients with various neurological disorders through innovative solutions.
Read more →NMTCGeneral
NeuroOne Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF Ablation System License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS Ma
NeuroOne Medical Technologies Corporation announced an expanded distribution agreement with Zimmer Biomet for the commercialization of its OneRF Ablation System, granting Zimmer exclusive rights for US distribution and select international markets. NeuroOne will receive an upfront payment of $3 million, with additional milestone payments possible based on performance criteria. The OneRF Ablation System, which is FDA cleared for both diagnostic and therapeutic use, has shown promise in reducing hospital stays and improving patient outcomes. The partnership is expected to significantly drive NeuroOne's sales revenue and profitability.
Read more →NMTCConferences/Events
NeuroOne Medical Technologies to Present at the 2024 ThinkEquity Conference
NeuroOne Medical Technologies Corporation (NMTC) announced its participation in the ThinkEquity Conference on October 30, 2024, in New York City. CFO Ron McClurg will present at the event, which aims to connect institutional investors and industry professionals. The conference will also feature one-on-one meetings and a live-streamed presentation, highlighting the company's commitment to advancing surgical care options for neurological disorders.
Read more →NMTCConferences/Events
NeuroOne Spinal Cord Stimulation Electrode Technology to be Featured at The Business of Pain Conference
NeuroOne Medical Technologies Corporation announced that its innovative paddle electrode technology for spinal cord stimulation will be showcased at The Business of Pain Conference. Dr. Sean Li, an expert in pain management, will present on this minimally invasive approach, which aims to improve treatment for chronic lower back pain. The company estimates the spinal cord stimulation market to be approximately $3 billion, emphasizing the large patient population with unmet clinical needs. However, they acknowledge various risks associated with market acceptance and technology performance.
Read more →NMTCGeneral
NeuroOne Announces Breakthrough Case Completed with OneRF™ Ablation System at the University Hospitals in Cleveland
NeuroOne Medical Technologies Corporation announced a successful breakthrough procedure using its OneRF Ablation System at University Hospitals in Cleveland. The procedure involved forty-four ablations performed on a patient, who following the treatment is now seizure-free with reported improvements in mood and memory. The ablation sessions, guided by sEEG recordings, were well-tolerated and indicate a positive outcome. NeuroOne's CEO expressed excitement over the procedure's success and the potential for further clinical applications of their technology.
Read more →NMTCConferences/Events
NeuroOne to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced its upcoming virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference scheduled for September 9-11, 2024. Chief Operating Officer Chris Volker will present on demand starting at 7:00 a.m. ET on September 9. The company is focused on advancing minimally invasive technologies for neurological disorders, with potential applications in various medical fields. However, the company faces inherent risks such as market acceptance and regulatory compliance.
Read more →NMTCGeneral
NeuroOne Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
NeuroOne Medical Technologies Corporation (NMTC) announced its financial results for the third quarter of fiscal 2024, reporting a product revenue increase to $826,000 from $630,000 in the same period last year. Key achievements include the completion of the first RF ablation cases with their OneRF Ablation System and the signing of a non-binding term sheet with a strategic partner for distribution. Despite progress, the company reported a net loss of $2.8 million, with cash and cash equivalents down to $1.6 million. The overall financial outlook reflects a mix of positive developments and challenges in revenue and costs.
Read more →NMTCConferences/Events
NeuroOne to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14
NeuroOne Medical Technologies Corporation will host a conference call on August 14, 2024, to discuss its financial results for the third quarter of fiscal year 2024 and provide a corporate update. The company specializes in minimally invasive solutions for neurological disorders and aims to improve patient outcomes. The results will cover the period ending June 30, 2024, with additional information about the company's future directions expected during the call.
Read more →NMTCGeneral
NeuroOne Announces $2.65 Million Equity Financing And $3.0 Million Credit Facility
NeuroOne Medical Technologies Corporation announced the closing of a $2.65 million equity financing and a $3 million credit facility. The funds will be used for commercializing their OneRF Ablation System and supporting operations while they negotiate a potential distribution agreement with a global medical technology partner. The partnership remains contingent on due diligence and the execution of definitive agreements. The company aims to complete these arrangements by the end of the third calendar quarter.
Read more →NMTCPhases
NeuroOne Announces First in Human Ablations Completed with OneRF™ Ablation System
NeuroOne Medical Technologies Corporation announced the successful completion of the first human ablations using its OneRF Ablation System in a patient suffering from multifocal epilepsy. Five ablations were performed at the patient's bedside, which not only reduced the time and costs associated with operating room procedures but also confirmed the effectiveness through post-ablation sEEG recordings. The company estimates a significant market potential for brain ablation therapy, reflecting a commitment to expanding applications of their technology in the future.
Read more →NMTCFDA Updates
NeuroOne Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation
NeuroOne Medical Technologies Corporation announced that the Centers for Medicare and Medicaid Services has approved a new ICD-10-PCS code for its OneRF Ablation procedure. Effective October 1, 2024, this code aims to facilitate broader recognition and adoption of the OneRF technology within the healthcare system. NeuroOne anticipates that this new coding will help reduce hospital stays and improve patient safety while addressing unmet clinical needs in the brain ablation market. The company sees considerable growth potential in this market segment.
Read more →NMTCGeneral
NeuroOne Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
NeuroOne Medical Technologies Corporation (NMTC) has reported its financial results for the second quarter of fiscal year 2024, highlighting significant revenue growth from its sEEG product line and the initiation of the OneRF Ablation System launch, which has received FDA clearance. Despite this, the company reported a net loss of $2.9 million, though this was an improvement over the previous year's loss. Cash reserves have decreased, and operating expenses remain substantial, indicating financial pressures amidst their advances in technology and market presence.
Read more →NMTCConferences/Events
NeuroOne to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14
NeuroOne Medical Technologies Corporation will hold a conference call and webcast on May 14, 2024, to discuss its financial results for the second quarter of fiscal year 2024, which ended on March 31, 2024. The company, focused on surgical solutions for neurological disorders, aims to improve patient care and reduce procedural costs. This update aims to inform stakeholders about the company's current status and future direction. NeuroOne's expanding applications indicate a commitment to innovation within the medical technology field.
Read more →NMTCGeneral
NeuroOne CEO Dave Rosa Featured on Bloomberg Technology
NeuroOne Medical Technologies Corporation's CEO, Dave Rosa, appeared on Bloomberg Technology to discuss the first implantation of the OneRF™ Ablation electrode. This milestone was part of the company's limited commercial launch of the Ablation System, which aims to enhance surgical care for neurological disorders. The unique technology allows for both diagnostic and therapeutic uses from a single device. Rosa expressed optimism about its potential applications in gene therapy and monitoring brain regions for conditions like epilepsy and Alzheimer’s disease.
Read more →NMTCFDA Updates
NeuroOne Announces First Implant of OneRF™ Ablation Electrodes
NeuroOne Medical Technologies Corporation has announced the successful first implant of its OneRF™ Ablation electrode, which was granted FDA 510(k) clearance for creating RF lesions in nervous tissue. This innovative technology is poised to improve surgical care for patients with neurological disorders, specifically epilepsy. The ablation system, used alongside the newly implanted sEEG electrodes, allows for simultaneous monitoring and treatment of seizure-causing areas in the brain. With a projected brain ablation market exceeding $100 million, NeuroOne aims to expand its offerings to address various neurological conditions.
Read more →NMTCGeneral
NeuroOne CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.
NeuroOne Medical Technologies Corporation (NMTC) CEO Dave Rosa was featured on Fox Business Network's Varney & Co., discussing the company's latest advancements in medical technology. Rosa introduced the OneRF™ Ablation System, a combination diagnostic and therapeutic device designed to improve surgical care for neurological disorders. The system aims to enhance patient outcomes while reducing hospital visits and related costs. NeuroOne is targeting treatments for conditions such as epilepsy and Parkinson's disease, highlighting its commitment to innovation in the healthcare sector.
Read more →NMTCFDA Updates
NeuroOne Initiates Limited Commercial Launch of OneRF Ablation System First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added
NeuroOne Medical Technologies Corporation has initiated a limited commercial launch of its OneRF Ablation System, an FDA-cleared device capable of both recording and ablating nervous tissue. The launch begins earlier than expected, with systems shipping to selected centers by the end of March 2024. CEO Dave Rosa highlighted the system's potential benefits, including reduced hospital stays and adverse events, while also indicating plans for the device's broader applications in various neurological conditions. The ablation market is viewed as having significant growth prospects due to unmet clinical needs.
Read more →NMTCGeneral
NASDAQ: NMTC NeuroOne Medical Technologies Corporation March 2024 2 Safe Harbor Statements This presentation and any information included in this presentation are strictly confidential and should not be discussed outside
NeuroOne Medical Technologies Corporation (NMTC) has received FDA clearance for its OneRF Ablation system aimed at treating various neurological conditions, leveraging EVO sEEG electrodes. The company is pursuing partnerships to enhance its market presence and develop next-generation electrode technologies. However, there are inherent risks, such as potential delays in commercialization and challenges in securing reimbursement for its products. Despite these challenges, the outlook is generally positive given their strategic initiatives and innovations in medical technology.
Read more →NMTCConferences/Events
NeuroOne to Participate in the 36th Annual Roth Conference
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced its participation in the upcoming 36th Annual Roth Conference from March 17-19, 2024, in Dana Point, California. CEO Dave Rosa and CFO Ron McClurg will hold individual meetings with institutional investors and analysts. The company aims to enhance surgical care for patients with neurological disorders and may explore various applications, including artificial intelligence. The participation in this conference highlights NeuroOne's commitment to innovation in the medical technology field.
Read more →NMTCGeneral
NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NeuroOne Medical Technologies Corporation announced an equity award as part of its 2021 Inducement Plan for a new employee, complying with Nasdaq Listing Rule 5635(c)(4). The award includes an option to purchase 65,000 shares at an exercise price of $1.07, with a vesting schedule that rewards long-term employment. This initiative highlights NeuroOne's commitment to enhancing its workforce and advancing its innovative medical technology solutions for neurological disorders.
Read more →NMTCGeneral
NeuroOne Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
NeuroOne Medical Technologies Corporation has reported its financial results for the first quarter of fiscal year 2024, highlighting the FDA clearance of its OneRF Ablation System, a breakthrough device that combines diagnostic and therapeutic capabilities. The clearance marks a significant achievement for the company, which plans to initiate a limited commercial launch in the second quarter of 2024. Despite product revenue increasing to $978,000, the company faced a net loss of $3.3 million, up from $1.7 million in the same quarter of the previous year. Additionally, collaboration revenues saw a notable decline, raising concerns about financial stability moving forward.
Read more →NMTCConferences/Events
NeuroOne to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
NeuroOne Medical Technologies Corporation will announce its first quarter fiscal year 2024 financial results on February 13, 2024. The company, dedicated to enhancing surgical options for neurological disorders, will also offer a corporate update during a conference call and webcast. The results pertain to the quarter that ended on December 31, 2023. NeuroOne aims to provide innovative solutions for various neurological conditions, reflecting its commitment to improving surgical care.
Read more →NMTCGeneral
NeuroOne Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its fiscal fourth quarter and full year 2023 financial results. The company reported significant growth in product revenue, which soared to $742,000 in Q4 from $69,000 the previous year. Notably, it secured FDA clearance for its OneRF Ablation System, marking a major milestone in its strategic plan. However, despite these advancements, the company faced an increase in net loss and a decline in cash reserves over the fiscal year.
Read more →NMTCFDA Updates
NeuroOne Receives FDA 510(k) Clearance to Market its OneRF Ablation System First FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benef
NeuroOne Medical Technologies Corporation has received FDA 510(k) clearance to market its OneRF Ablation System, a unique sEEG-guided RF system capable of performing both diagnostic and therapeutic functions in neurosurgery. This marks NeuroOne's third FDA-cleared device and indicates a promising future for the company's technology in improving surgical outcomes for patients with neurological disorders. The commercial launch is targeted for the first half of 2024. The approval comes as a significant milestone for NeuroOne, which aims to transform neurosurgery practices and improve patient care.
Read more →NMTCConferences/Events
NeuroOne to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14
NeuroOne Medical Technologies Corporation (NMTC) plans to host a conference call on December 14, 2023, to discuss its financial results for the fourth quarter and fiscal year ending September 30, 2023. The conference aims to provide a corporate update and insights into the company’s operations and strategies in advancing medical technologies for neurological disorders. NeuroOne specializes in developing minimally invasive solutions for treating conditions such as epilepsy and chronic pain among others. Interested participants can join the call via provided dial-in numbers.
Read more →NMTCGeneral
NeuroOne Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe Patent allowance strengthens IP portfolio and positions company in pursuing drug delivery using its neural probes
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has announced that the USPTO has issued a Notice of Allowance for a patent application concerning a novel neural probe capable of delivering treatment agents alongside its standard role as a neural electrode. This development is expected to enhance the company's intellectual property position and attract potential partnerships with biopharma companies. NeuroOne aims to leverage this technology in various neurological applications, indicating a commitment to advancing minimally invasive treatment options.
Read more →NMTCGeneral
NeuroOne Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Volker strengthens existing management team in areas of commercializa
NeuroOne Medical Technologies Corporation has appointed Christopher R. Volker as Chief Operating Officer to enhance its management team. With a strong background in commercial expansion and business development, Volker's entry is expected to bolster the company's growth in neurological solutions. In conjunction with his hire, NeuroOne announced an equity award under Nasdaq Listing Rule 5635(c)(4). The company is positioned to improve patient outcomes with its innovative technologies but faces various industry and operational risks.
Read more →NMTCFDA Updates
NeuroOne Provides Progress Update on FDA 510(k) Submission for OneRF Ablation System Feedback from responses to FDA anticipated in 30 days Commercialization remains on track in first half of 2024 pending FDA clearance Pr
NeuroOne Medical Technologies Corporation has provided an update regarding its FDA 510(k) submission for the OneRF Ablation System. The company expects to receive feedback from the FDA in about 30 days, allowing it to prepare for commercialization, which is anticipated in the first half of 2024. The OneRF system, notable for being the first sEEG-guided RF system, is designed to improve procedures in neurosurgery by offering both recording and ablation capabilities. The technology is expected to provide significant benefits, including safer clinical outcomes and cost reduction.
Read more →NMTCConferences/Events
NeuroOne to Present at the ThinkEquity Conference on October 19, 2023
NeuroOne Medical Technologies Corporation will have its CFO, Ron McClurg, present at the ThinkEquity Conference on October 19, 2023, in New York City. The company's focus is on enhancing surgical care options for patients with neurological disorders through minimally invasive technologies. This presentation may provide insights into NeuroOne's innovative approaches and future opportunities within the medical technology sector.
Read more →NMTCConferences/Events
NeuroOne to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NeuroOne Medical Technologies Corporation announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference, set to take place from September 11-13, 2023. The company will provide a pre-recorded presentation by CFO Ron McClurg, accessible to registered investors starting September 11. NeuroOne specializes in minimally invasive solutions for various neurological disorders, which may lead to improved outcomes for patients and reduced procedural costs.
Read more →NMTCGeneral
NeuroOne Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
NeuroOne Medical Technologies Corporation announced its financial results for the third quarter of fiscal year 2023, highlighting significant revenue growth and operational updates. The company reported product revenue of $630,000, a notable increase from $32,000 in the same period last year. Additionally, NeuroOne's CEO mentioned progress in the commercial launch of the Evo sEEG electrode and positive feedback from the FDA regarding the OneRF Ablation System. However, the company also experienced higher operating expenses and a larger net loss compared to the prior year.
Read more →NMTCGeneral
NeuroOne to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14
NeuroOne Medical Technologies Corporation (NMTC) is scheduled to report its third quarter financial results for the fiscal year 2023 on August 14, 2023. The conference call will discuss results from the quarter ending June 30, 2023. The company aims to enhance surgical care options for patients with neurological disorders and is exploring new applications in other medical areas. This presentation highlights NeuroOne's focus on advancing technology and patient care outcomes.
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
NeuroOne Medical Technologies Corporation has announced a proposed public offering of its common stock, with the aim to raise capital for various initiatives. The company plans to utilize the proceeds to support the commercial launch of its EVO sEEG electrode, an FDA submission for the OneRF ablation system, and the design of a new drug delivery electrode. The offering remains contingent on market conditions and the terms are not guaranteed.
Read more →NMTCFDA Updates
NeuroOne Submits 510(k) Application to FDA for OneRF™ Ablation System
NeuroOne Medical Technologies Corporation has submitted a 510(k) application to the FDA for its OneRF Ablation System, a pioneer in sEEG-guided radio frequency ablation technology. This system combines both diagnostic and therapeutic capabilities, potentially transforming care for patients with neurological disorders. If approved, it will provide a safer, cost-effective solution by reducing the need for multiple invasive procedures. The company anticipates initial feedback from the FDA by August 7, 2023.
Read more →NMTCPhases
NeuroOne Announces First Clinical Case Using Evo sEEG Electrode in Robotic Neurosurgery
NeuroOne Medical Technologies Corporation has successfully executed its first clinical case using the Evo sEEG electrode in robotic neurosurgery at Cleveland Clinic. This groundbreaking procedure, conducted by Dr. William Bingaman, utilized the ROSA One Brain robotic platform from Zimmer Biomet, marking a significant milestone in their partnership. The Evo sEEG electrode technology is now marketed in the U.S., with the potential to improve outcomes for various neurological conditions. The company aims to advance its technology further following FDA clearance and positive initial results from this clinical application.
Read more →NMTCGeneral
NeuroOne to Report Second Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on May 11
NeuroOne Medical Technologies Corporation will report its financial results for the second quarter of fiscal year 2023 on May 11, 2023. The announcement includes a conference call to discuss these results and provide a corporate update. The company is dedicated to developing minimally invasive technologies for various neurological disorders, aiming to enhance patient care and reduce costs associated with surgical procedures. NeuroOne is also exploring applications in additional medical fields, such as mood disorders and artificial intelligence.
Read more →NMTCGeneral
NeuroOne Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
NeuroOne Medical Technologies Corporation reported its second quarter financial results for fiscal year 2023, showing significant growth in product and collaboration revenues compared to the same period last year. The commercial launch of the Evo sEEG electrode has been announced, along with continuing advancements in their OneRF ablation system, which is expected to secure FDA submission shortly. However, the company reported a net loss of $3.5 million, an increase from the previous year's quarter, and a notable decrease in cash reserves is evident from their balance sheet. Overall, while there are promising developments, financial challenges remain a concern.
Read more →NMTCPhases
NeuroOne Announces First Clinical Case Using Evo sEEG Electrode Performed at Mayo Clinic
NeuroOne Medical Technologies Corporation has announced a major milestone, successfully conducting its first clinical case using the Evo sEEG electrode at Mayo Clinic. This marks a significant advancement in their technology designed to improve surgical options for patients with neurological disorders. The procedure was performed under the oversight of Dr. Jamie Van Gompel, demonstrating the electrodes' performance aligned with company objectives. With an estimated $100 million market opportunity for diagnostic procedures, NeuroOne aims to enhance adoption of its technology in the U.S. through partnerships.
Read more →NMTCConferences/Events
NeuroOne to Present at the Sidoti Micro-Cap Virtual Conference on May 10
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has announced that CFO Ron McClurg will present at the Sidoti Micro-Cap Virtual Conference on May 10-11, 2023. The presentation aims to highlight the company's advancements in medical technology targeting neurological disorders. Investors are encouraged to request one-on-one meetings during the conference.
Read more →NMTCGeneral
NeuroOne Announces U.S. Commercial Launch of Evo sEEG Electrodes
NeuroOne Medical Technologies Corporation has successfully launched its Evo sEEG electrode product line in the U.S., marking a significant advancement in their business. This new product is designed to enhance surgical outcomes for patients with neurological disorders, and it pairs with Zimmer Biomet’s ROSA One robotic platform for improved procedures. The company anticipates capitalizing on a $100 million market for diagnostic brain mapping, particularly in epilepsy treatment. While the partnership and technology offer substantial opportunities, there are inherent risks related to market adoption and regulatory uncertainties.
Read more →NMTCGeneral
NeuroOne Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) reported its financial results for the first quarter of fiscal year 2023, highlighting a significant rise in product and collaboration revenue. The CEO announced FDA clearance for their Evo sEEG electrode, central to their commercialization strategy with Zimmer Biomet, and indicated plans to seek 510(k) clearance for their OneRF Ablation System. Despite a reduction in net loss from the previous year, the company faces challenges with increased operating expenses and a decline in cash reserves. Future milestones include exploring new markets and potential partnerships to enhance their technology offerings.
Read more →NMTCGeneral
NeuroOne Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results
NeuroOne Reports Fiscal Fourth Quarter
and Full Fiscal Year 2022 Financial Results
EDEN PRAIRIE, Minn., December 22, 2022 (PR
Newswire) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical
technology company focused on improving
Read more →NMTCFDA Updates
NeuroOne Receives FDA 510(k) Clearance to Market its Evo sEEG System for Less than 30 Day Use Company focused on manufacturing ramp for commercialization in partnership with Zimmer Biomet
Receives FDA 510(k) Clearance to Market its Evo sEEG System for Less than 30 Day Use
on manufacturing ramp for commercialization in partnership with Zimmer Biomet
Minn. - October 25, 2022 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a me
Read more →NMTCGeneral
FACT SHEET Fall 2022 Nasdaq: NMTC https://n1mtc.com Advancing Neuroscience One Neuron at a Time. NeuroOne Medical Technologies Corporation is a medical technology company focused on the development and commercialization
FACT SHEET Fall 2022 Nasdaq: NMTC https://n1mtc.com Advancing Neuroscience One Neuron at a Time. NeuroOne Medical Technologies Corporation is a medical technology company focused on the development and commercialization of minimally invasive and high - definition/high - precision
Read more →NMTCGeneral
NeuroOne Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
PRAIRIE, Minn., August 11, 2022 (PR Newswire) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne"
or the "Company"), a medical technology company focused on improving surg
Read more →NMTCGeneral
NeuroOne Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo sEEG Electrode Amendment provides Zimmer Biomet with 350,000 warrants with exercise price of $3.00 per share
NeuroOne Announces $3.5 Million
Accelerated Milestone Payment from Zimmer Biomet for Evo sEEG Electrode
Zimmer Biomet with 350,000 warrants with exercise price of $3.00 per share
EDEN PRAIRIE, Minn., August 3, 2022 (PR
Newswire) -- NeuroOne Medical Technologies Corporation (N
Read more →NMTCConferences/Events
NeuroOne Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders Letter recaps key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond
Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders
recaps key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond
PRAIRIE, Minn., June 2, 2022 (PR Newswire) -- NeuroOne Medical Technologies Corporatio
Read more →NMTCFDA Updates
NeuroOne Provides Evo sEEG Update The Evo sEEG electrode 510(k) cleared for temporary (less than 24 hours) use remains in effect and the Company will explore the opportunity to market the device for intraoperative use.
Provides Evo sEEG Update
sEEG electrode 510(k) cleared for temporary (less than 24 hours) use remains in effect and the Company will explore the
opportunity to market the device for intraoperative use.
Minn., May 16, 2022 (PR Newswire) -- NeuroOne Medical Technologies Corporat
Read more →NMTCGeneral
NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., May 12, 2022 (PR
Newswire) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical
technology company focused on improving
Read more →NMTCGeneral
NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
NeuroOne Reports First Quarter
Fiscal Year 2022 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., February 14, 2022 (PR
Newswire) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical
technology company focused
Read more →NMTCGeneral
NeuroOne Reports Fourth Fiscal Quarter and Full Fiscal Year 2021 Financial Results and Provides Corporate Update
Reports Fourth Fiscal Quarter and Full Fiscal Year 2021
Results and Provides Corporate Update
EDEN PRAIRIE, Minn., December 15, 2021 (PR
Newswire) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical
technology company focused on
Read more →NMTCFDA Updates
NeuroOne Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo sEEG Electrode Company's second FDA 510(k) clearance received
NeuroOne Medical Technologies
Corporation Receives FDA 510(k) Clearance for its Evo sEEG Electrode
Company's second FDA 510(k) clearance
EDEN PRAIRIE, Minn. - September
7, 2021 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical tec
Read more →NMTCGeneral
NeuroOne Reports Third Quarter Fiscal 2021 Financial Results and Corporate Update EDEN PRAIRIE, Minn. -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company
Reports Third Quarter Fiscal 2021 Financial Results and Corporate Update
PRAIRIE, Minn. -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical
technology company focused on improving surgical care options and outcomes for patients su
Read more →NMTCFDA Updates
NeuroOne Announces Approval for Nasdaq Capital Market Listing;Trading Expected to Commence Tomorrow May 26th, 2021 Under the Symbol NMTC EDEN PRAIRIE, Minn. May 25 th , 2021 /PRNewswire/ -- NeuroOne Medical Technologies
NeuroOne Announces Approval for Nasdaq Capital Market Listing;Trading
Expected to Commence Tomorrow May 26th, 2021 Under the Symbol NMTC
EDEN PRAIRIE, Minn. May 25th,
2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a
medi
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces Reverse Stock Split as Part of Uplisting Strategy to Major Exchange Eden Prairie, MN
Medical Technologies Corporation Announces Reverse Stock Split as Part of Uplisting Strategy to Major Exchange
Eden Prairie, MN - March 31, 2021- NeuroOne
Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces Successful Completion of First Performance Milestone in Zimmer Biomet Agreement Eden Prairie, MN
Medical Technologies Corporation Announces Successful Completion of First
Milestone in Zimmer Biomet Agreement
Prairie, MN - February 23, 2021- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company),
a medical technology company focused on improving s
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces Private Placement Eden Prairie, MN
Medical Technologies Corporation Announces Private Placement
Prairie, MN - January 12, 2021 - NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical
technology company focused on improving surgical care options and outcomes for patients suffering from neur
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Appoints Ronald McClurg, Experienced Financial Industry Executive, as Chief Financial Officer Eden Prairie, MN
Medical Technologies Corporation Appoints Ronald McClurg,
Experienced Financial Industry Executive, as Chief Financial Officer
Prairie, MN - January 7, 2021- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical
technology company focused on improving su
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Provides Commercialization Update for EVO Cortical Electrode Eden Prairie, MN
Technologies Corporation Provides Commercialization Update for EVO Cortical Electrode
Eden Prairie, MN - October 6, 2020- NeuroOne
Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options
and outcomes for
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Reduces Debt by $3.3 Million and Strengthens Balance Sheet Company Preparing for Commercialization of Thin Film Electrodes Technology Eden Prairie, MN
Medical Technologies Corporation Reduces Debt by $3.3 Million and Strengthens Balance Sheet
Preparing for Commercialization of Thin Film Electrodes Technology
Eden Prairie, MN - July 28, 2020 - NeuroOne
Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical techno
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Enters into Exclusive Development and Distribution Agreement for Commercialization of Diagnostic Evo Cortical Electrode Eden Prairie, MN
NeuroOne Medical Technologies
Corporation Enters into Exclusive Development and Distribution Agreement for Commercialization of Diagnostic Evo Cortical Electrode
Eden Prairie, MN- July 22, 2020- NeuroOne
Medical Technologies Corporation (OTCQB: NMTC), a medical technology comp
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Company Overview High - definition, minimally invasive platform electrode technology for recording & treatment of neurological disorders such as epilepsy, Parkinson's Disease and
NeuroOne Medical Technologies Corporation Company Overview High - definition, minimally invasive platform electrode technology for recording & treatment of neurological disorders such as epilepsy, Parkinson's Disease and Failed Back Surgery Syndrome
FORWARD LOOKING STATEMENT S 2
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Appoints Edward Andrle as New Board Member Eden Prairie, Minn.
NeuroOne Medical Technologies Corporation
Appoints Edward Andrle as New Board Member
Eden Prairie, Minn., February 24, 2020
NeuroOne Medical Technologies Corporation
(OTCQB: NMTC), a medical technology company focused on improving surgical care options and outcomes for patien
Read more →NMTCFDA Updates
NeuroOne Medical Technologies Corporation Receives FDA 510(k) Clearance for Evo Cortical Electrode The Company believes that the Evo Cortical Electrode is the first cortical electrode to receive FDA 510(k) clearance that
NeuroOne Medical Technologies
Corporation Receives FDA 510(k) Clearance for Evo Cortical Electrode
The Company believes that the
Evo Cortical Electrode is the first cortical electrode to receive FDA 510(k) clearance that uses thin film printed
microcircuit technology manufact
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces First Sale of sEEG Depth Electrode Company's sEEG Electrode will be used for non-human research purposes by the Cleveland Clinic Foundation MINNETONKA, MN / ACCESSWIRE
Technologies Corporation Announces First Sale of sEEG Depth Electrode
Company's sEEG Electrode will be used
for non-human research purposes by the Cleveland Clinic Foundation
MINNETONKA, MN / ACCESSWIRE /
September 23, 2019 / NeuroOne Medical Technologies Corporation (OTCQB:
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces Fiscal Third Quarter 2019 Financial Results and Provides a Corporate Update Minnetonka, MN
Medical Technologies Corporation Announces Fiscal Third Quarter 2019 Financial Results and Provides a Corporate Update
MN - August 14, 2019 - NeuroOne Medical Technologies Corporation (OTCQB: NMTC), a
medical device company focused on the development and commercialization of th
Read more →NMTCGeneral
NeuroOne Medical Technologies Announces Hiring Of Senior Staff
EDEN PRAIRIE, Minn., Jan. 30, 2019 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the hiring of L
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces Appointments to Artificial Intelligence Advisory Board
NeuroOne introduces five members of Artificial Intelligence Advisory Board focused on AI and neuromodulation applications
EDEN PRAIRIE, Minn., Nov. 13, 2018 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC), a medical technology company focused on impro
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Appoints Neuroscience Expert Kip Ludwig, PhD To Chair Artificial Intelligence Advisory Board NeuroOne creates new advisory board focused on artificial intelligence and neuromodul
NeuroOne Medical Technologies Corporation Appoints Neuroscience
Expert Kip Ludwig, PhD To Chair Artificial Intelligence Advisory Board
NeuroOne creates new advisory board focused on artificial
intelligence and neuromodulation applications
NeuroOne Medical Technologies Corpora
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Issues Statement Regarding Recent Promotional Activity Involving Its Common Stock NeuroOne Medical Technologies Corporation (OTCQB:NMTC), a medical technology company focused on
Medical Technologies Corporation Issues Statement Regarding Recent Promotional Activity Involving Its Common Stock
Medical Technologies Corporation (OTCQB:NMTC), a medical technology company focused on improving surgical care options and outcomes
for patients suffering from neu
Read more →NMTCGeneral
NeuroOne Medical Technologies Announces 2017 Achievements and Provides Corporate Update
EDEN PRAIRIE, Minn., May 23, 2018 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (OTCQB:NMTC) today reported business highlights for the fiscal year ended December 31, 2017 and outlined plans for 2018.
Dave Rosa, CEO of NeuroOne stated, “In 2017, we made great pro
Read more →NMTCGeneral
NeuroOne Medical Technologies Corporation Announces Appointment to Scientific Advisory Board
EDEN PRAIRIE, Minn., May 17, 2018 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NMTC), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the appointment of Dr.
Read more →NMTCGeneral
NeuroOne, Inc.
FINANCIAL STATEMENTS
Condensed Financial Statements (unaudited) Condensed Balance Sheets (unaudited) 3 Condensed Statements of Operations (unaudited) 4 Condensed Statements of Cash Flows (unaudited) 5 Notes to Condensed Financial Statements (unaudited) 6 - 18
Condensed Balance
Read more →